Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma-A Regression Analysis of Dose-Response [0.03%]
蒽环类和放射治疗后的淋巴瘤晚期心脏毒性：剂量反应的回归分析
Lotte Nygård,Ivan Richter Vogelius,Klaus F Kofoed et al.
Lotte Nygård et al.
Late cardiac toxicity after radiation therapy and/or systemic therapy with anthracyclines for lymphomas is a serious concern. To estimate the risks with different treatment combinations, reliable estimates of the dose-response relationships...
Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High-Risk Diffuse Large B Cell Lymphoma [0.03%]
DNA修复抑制剂和细胞毒性药物合成致死组合靶向治疗高危弥漫大B细胞淋巴瘤
Sara Ovejero,Julie Devin,Laura Alibert et al.
Sara Ovejero et al.
Diffuse large B-cell lymphoma (DLBCL) is the most common hematological malignancy. More than half of DLBCL patients achieve long-term remission after treatment, but a third relapse after conventional Rituximab (R)-based chemotherapy regimen...
Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [0.03%]
Loncastuximab治疗复发或难治性弥漫大B细胞淋巴瘤患者的不良反应管理
Narendranath Epperla,Adam J Olszewski,Emily C Ayers et al.
Narendranath Epperla et al.
Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma in the world. Treatment options for relapsed DLBCL in the third line and beyond include chimeric antigen receptor T-cell therapy, T-cell-engaging bispecifi...
Evaluation of Delayed Initiation of Lenalidomide Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma [0.03%]
自体和异基因造血干细胞移植后来那度胺维持治疗延迟启动的评估分析
Koji Kawamura,Nobuhiro Tsukada,Shun-Ichi Kimura et al.
Koji Kawamura et al.
Although allogeneic hematopoietic stem cell transplantation (allo-HCT) is considered a potentially curative therapy for multiple myeloma, disease progression after allo-HCT remains a major limitation. Post-transplant maintenance therapy may...
The Role of Different Risk Groups and Treatment Assignment Probabilities in Subgroup Analysis of Randomized Trials [0.03%]
随机试验中不同风险组和治疗分配概率在亚组分析中的作用
Vadim Lesan,Vlada Odaie,Cristian Munteanu
Vadim Lesan
Retrospective subgroup analyses can introduce significant bias in the estimation of hazard ratios (HRs), particularly when patient distributions across treatment arms are imbalanced. Such disparities can distort the validity of HR outcomes,...
Oncogenic IRF3 Signaling Promotes Diffused Large B-Cell Lymphoma Proliferation by Cyclin D3/CDK4-Dependent Cell Cycle Control [0.03%]
致癌性IRF3信号通过周期素D3/CDK4依赖型细胞周期调控促进弥漫性大B细胞淋巴瘤增殖
Bide Zhao,Linjing Shi,Xiao Yang
Bide Zhao
Diffuse large B-cell lymphoma (DLBCL), the most aggressive non-Hodgkin lymphoma subtype, is cured in 60%-70% of patients with frontline chemoimmunotherapy. For refractory/relapsed cases, deciphering DLBCL's molecular drivers could unveil ne...
Lomustine, Etoposide and Cyclophosphamide as Conditioning for Auto-HCT in Lymphomas [0.03%]
用于淋巴瘤自体造血干细胞移植的洛莫司汀、依托泊苷和环磷酰胺预处理方案
Rafaella Cabral Samico,Júlia Diniz Ferreira,Christianne Tolêdo de Souza Leal et al.
Rafaella Cabral Samico et al.
Real World Incidence and Etiology of Infectious Complications in Adults With Ph-Negative Acute Lymphoblastic Leukemia Treated With the Pediatric-Inspired GIMEMA LAL1913 Program. A Campus All Study [0.03%]
儿童急性淋巴细胞白血病治疗方案GIMEMA LAL1913在Ph阴性成人患者中感染并发症的发病率和病因：CAMLAT研究
Patrizia Zappasodi,Ludovica Calabretta,Virginia Valeria Ferretti et al.
Patrizia Zappasodi et al.
Infections often complicate pediatric-inspired treatments for adult Philadelphia-negative acute lymphoblastic leukemia (Ph- ALL). Literature data on these complications are difficult to interpret due to the heterogeneity of types of infecti...
Multicenter Study
Hematological oncology. 2025 Sep;43(5):e70121. DOI:10.1002/hon.70121 2025
Re: Long-Term Outcomes and Management Strategies With DA-R-EPOCH in Primary Mediastinal B-Cell Lymphoma: Insights From a Single-Center Experience [0.03%]
DA-R-EPOCH治疗原发 mediastinal B细胞淋巴瘤的长期疗效及管理策略——单一中心经验分享
Theodoros P Vassilakopoulos,Alexia Piperidou,Zois Mellios et al.
Theodoros P Vassilakopoulos et al.
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study [0.03%]
DANTE研究：尼洛替尼减量治疗后慢性髓性白血病患者无治疗缓解的96周更新数据
Alessandra Iurlo,Massimo Breccia,Fabio Stagno et al.
Alessandra Iurlo et al.
Treatment-free remission (TFR) in chronic myeloid leukemia (CML) can be considered for patients in sustained deep molecular response (DMR) who can discontinue tyrosine kinase inhibitors (TKIs) while maintaining responses. Studies suggest th...
Clinical Trial
Hematological oncology. 2025 Sep;43(5):e70126. DOI:10.1002/hon.70126 2025